{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-043227","form_type":"8-K","ticker":"ASRT","cik":"0001808665","company_name":"Assertio Holdings, Inc.","filed_at":"2026-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.953113+00:00","generated_at":"2026-05-15T06:24:54.361872+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Assertio completes sale of six product franchises to Cosette for $35M cash plus up to $35M contingent payments","bullets":["Products sold: INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, OTREXUP; deal closed April 8, 2026.","Upfront cash $35M; potential milestones up to $32M (SYMPAZAN, INDOCIN, OTREXUP) and SPRIX earn-out (quality approval $1M, 8% gross profits through 2027, $2M if 2027 net sales >$7M).","Pro forma continuing ops: 2025 net loss ~$31.3M (historical $30.4M); 2024 net loss ~$27.5M (historical $21.6M).","Estimated transaction costs ~$1.9M; estimated gain on disposal ~$16M.","Company also divested Assertio Therapeutics in May 2025; results removed from continuing ops in pro forma."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-043227","json":"https://secwatch.observer/filing/0001104659-26-043227.json","markdown":"https://secwatch.observer/filing/0001104659-26-043227.md","text":"https://secwatch.observer/filing/0001104659-26-043227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808665/000110465926043227/0001104659-26-043227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808665/000110465926043227/tm2611405d7_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:24:54.361872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}